Oncogenic K-Ras Activates p38 to Maintain Colorectal Cancer Cell Proliferation during MEK Inhibition

Background: Colon carcinomas frequently contain activating mutations in the K-ras proto-oncogene. K-ras itself is a poor drug target and drug development efforts have mostly focused on components of the classical Ras-activated MEK/ERK pathway. Here we have studied whether endogenous oncogenic K-ras...

Descripción completa

Detalles Bibliográficos
Autores principales: van Houdt, Winan J., de Bruijn, Menno T., Emmink, Benjamin L., Raats, Danielle, Hoogwater, Frederik J. H., Rinkes, Inne H. M. Borel, Kranenburg, Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2010
Materias:
Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619241/
https://www.ncbi.nlm.nih.gov/pubmed/20413844
http://dx.doi.org/10.3233/CLO-2010-0521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619241/
https://www.ncbi.nlm.nih.gov/pubmed/20413844
http://dx.doi.org/10.3233/CLO-2010-0521

Ejemplares similares